This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Monopar Therapeutics’s 8K filing here.
About Monopar Therapeutics
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
See Also
- Five stocks we like better than Monopar Therapeutics
- Which Wall Street Analysts are the Most Accurate?
- 5 Reasons DraftKings Stock Looks Promising in the New Year
- What is the FTSE 100 index?
- Cybersecurity Stocks: 1 Immediate Buy and 1 Dip Opportunity
- Technology Stocks Explained: Here’s What to Know About Tech
- The Next 2 AI Winners Have Triple-Digit Upside Potential
